Tadalafil
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 40mg once daily
Effectiveness
78%
Safety Score
60%
Clinical Trials
44
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
40mg once daily
Time to Effect
Weeks to months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,500
Monitoring:$4,500
Side Effect Mgmt:$300
Total Annual:$7,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$20,857
Cost per Remission
$104,286
Tadalafil Outcomes
for Pulmonary Arterial Hypertension
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+35%
Remission Rate
+7%
Common Side Effects
Headache
+30%
Flushing
+15%
Dyspepsia
+12%
Nasal Congestion
+8%
Back Pain
+8%
Active Clinical Trials
1 active trial recruiting for Tadalafil in Pulmonary Arterial Hypertension
Comparison of Sequential to Initial Combination Therapy in PAH
NCT06968962RECRUITINGNA
376 participants
INTERVENTIONAL
Hangzhou, China
Started: May 14, 2025
Completed Clinical Trials
13 completed trials for Tadalafil in Pulmonary Arterial Hypertension
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
NCT01066845COMPLETED
1.81K participants
OBSERVATIONAL
Started: Jan 1, 2010
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
NCT00125918COMPLETEDPHASE3
406 participants
INTERVENTIONAL
Tucson, United States +5 more
Started: Aug 1, 2005
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
NCT04483115COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Beijing, China +8 more
Started: Nov 16, 2020
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
NCT02558231COMPLETEDPHASE3
247 participants
INTERVENTIONAL
Phoenix, United States +57 more
Started: May 1, 2016
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
NCT01484431COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
Aurora, United States +15 more
Started: Jul 17, 2012
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
NCT00549302COMPLETEDPHASE3
357 participants
INTERVENTIONAL
Bend, United States +9 more
Started: Dec 1, 2005
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
NCT00617305COMPLETEDPHASE4
38 participants
INTERVENTIONAL
Mobile, United States +29 more
Started: Apr 1, 2008
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT01178073COMPLETEDPHASE3
610 participants
INTERVENTIONAL
Birmingham, United States +142 more
Started: Oct 1, 2010
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
NCT02891850COMPLETEDPHASE4
225 participants
INTERVENTIONAL
Phoenix, United States +80 more
Started: Jan 11, 2017
Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)
NCT01043627COMPLETED
100 participants
OBSERVATIONAL
Birmingham, United States +2 more
Started: Dec 1, 2009
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT03904693COMPLETEDPHASE3
187 participants
INTERVENTIONAL
Fullerton, United States +147 more
Started: Jul 29, 2019
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
NCT02484807COMPLETED
125 participants
OBSERVATIONAL
Heidelberg, Germany
Started: May 1, 2015
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
NCT01305252COMPLETEDPHASE4
21 participants
INTERVENTIONAL
Stanford, United States +1 more
Started: Jul 1, 2010
Showing 20 of 45 total trials